Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Merck & Co stock

MRK
US58933Y1055
A0YD8Q

Price

106.70
Today +/-
+5.57
Today %
+5.50 %

Merck & Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Merck & Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Merck & Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Merck & Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Merck & Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Merck & Co Stock Price History

DateMerck & Co Price
1/13/2025106.70 undefined
1/13/2025100.98 undefined
1/10/202599.25 undefined
1/8/202599.85 undefined
1/7/2025101.02 undefined
1/6/202599.72 undefined
1/3/202599.14 undefined
1/2/202599.17 undefined
12/31/202499.48 undefined
12/30/202498.37 undefined
12/27/202499.70 undefined
12/26/202499.87 undefined
12/24/202499.45 undefined
12/23/202499.37 undefined
12/20/202498.05 undefined
12/19/202499.52 undefined
12/18/202498.34 undefined
12/17/2024100.06 undefined
12/16/2024100.06 undefined

Merck & Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Merck & Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Merck & Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Merck & Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Merck & Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Merck & Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Merck & Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Merck & Co’s growth potential.

Merck & Co Revenue, EBIT and net profit per share

DateMerck & Co RevenueMerck & Co EBITMerck & Co Net Income
2029e74.98 B undefined29.71 B undefined26.94 B undefined
2028e77.83 B undefined32.4 B undefined29.3 B undefined
2027e76.01 B undefined33.4 B undefined29.02 B undefined
2026e72.1 B undefined31.45 B undefined27.01 B undefined
2025e67.94 B undefined28.53 B undefined24.23 B undefined
2024e64.62 B undefined24.08 B undefined19.81 B undefined
202360.12 B undefined4.07 B undefined365 M undefined
202259.28 B undefined20.31 B undefined14.52 B undefined
202148.7 B undefined15.57 B undefined13.05 B undefined
202041.52 B undefined10.93 B undefined7.07 B undefined
201939.12 B undefined10.09 B undefined9.84 B undefined
201842.29 B undefined11.31 B undefined6.22 B undefined
201740.12 B undefined9.96 B undefined2.39 B undefined
201639.81 B undefined9.94 B undefined3.92 B undefined
201539.5 B undefined8.61 B undefined4.44 B undefined
201442.24 B undefined9.35 B undefined11.92 B undefined
201344.03 B undefined9.22 B undefined4.4 B undefined
201247.27 B undefined10.5 B undefined6.17 B undefined
201148.05 B undefined10.1 B undefined6.26 B undefined
201045.99 B undefined6.75 B undefined859 M undefined
200927.43 B undefined4.7 B undefined12.85 B undefined
200823.85 B undefined6.21 B undefined7.79 B undefined
200724.2 B undefined5.94 B undefined3.27 B undefined
200622.64 B undefined3.74 B undefined4.43 B undefined
200522.01 B undefined5.88 B undefined4.63 B undefined
200422.97 B undefined6.76 B undefined5.83 B undefined

Merck & Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
3.253.563.554.135.065.946.557.678.69.6610.514.9716.6819.8323.6426.932.7140.3621.221.4522.4922.9722.0122.6424.223.8527.4345.9948.0547.2744.0342.2439.539.8140.1242.2939.1241.5248.759.2860.1264.6267.9472.176.0177.8374.98
-9.64-0.3416.3822.6017.3510.2917.1112.1412.328.6542.5911.4418.8719.2113.8021.6223.38-47.481.164.852.17-4.182.846.90-1.4315.0067.664.48-1.62-6.84-4.08-6.480.780.795.41-7.506.1317.3121.721.407.505.146.125.422.40-3.66
61.0659.9964.1467.5971.4774.3176.3476.8277.5178.3176.2060.1755.3053.0050.1248.2346.4044.3982.9081.3280.2778.3976.6173.4874.6276.5967.1260.0064.8965.2163.6164.0563.2266.0868.5069.1171.7372.1072.8170.9873.5368.4065.0561.3058.1556.7958.95
1.982.142.282.793.624.4155.896.677.5789.019.2210.5111.8512.9715.1817.9217.5717.4418.0518.0116.8616.6318.0618.2718.4127.5931.1830.8228.0127.0524.9726.3127.4829.2328.0629.9435.4642.0844.2000000
0.450.490.540.680.911.211.51.782.121.982.1733.343.884.615.255.896.827.287.156.835.834.634.433.277.7912.850.866.266.174.411.924.443.922.396.229.847.0713.0514.520.3719.8124.2327.0129.0229.326.94
-9.569.3325.2334.2233.1123.9619.1319.09-6.469.1738.3711.2816.3718.8913.7412.2315.816.74-1.81-4.46-14.64-20.57-4.28-26.33138.4665.04-93.32628.41-1.47-28.56170.66-62.73-11.75-38.93159.8258.25-28.2084.6511.27-97.495,328.4922.3011.467.440.98-8.07
-----------------------------------------------
-----------------------------------------------
2.662.642.572.552.482.42.42.372.362.312.312.552.542.492.472.442.42.352.322.282.252.232.22.192.192.142.273.123.093.0832.932.842.792.752.682.582.542.542.542.55000000
-----------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Merck & Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Merck & Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                                 
0.370.740.840.971.151.551.141.21.411.091.542.273.352.182.313.363.24.253.294.974.177.0915.648.718.235.499.612.214.9716.1417.4915.7213.4314.348.58.8610.458.068.113.197.09
0.710.810.860.911.081.021.271.351.551.742.092.352.52.662.883.374.095.265.225.424.023.632.933.313.373.536.947.698.547.977.186.636.487.026.877.076.787.859.239.4510.35
00000000000000000000000090600000000000000660723
0.570.570.540.580.660.660.780.890.991.181.641.661.872.152.152.622.853.023.582.962.551.91.661.771.882.098.055.876.256.546.235.574.74.875.15.445.986.315.955.916.36
0.090.060.060.060.120.160.220.330.360.390.460.640.90.740.880.871.121.060.881.030.780.860.831.430.6683.843.33.424.214.794.695.144.394.34.54.285.546.996.517.65
1.732.182.312.513.013.393.413.774.314.45.736.928.627.738.2110.2311.2613.612.9614.3911.5313.4821.0515.2315.0519.1128.4329.0633.1834.8635.6932.6129.7530.6124.7725.8827.4827.7630.2735.7232.17
1.721.911.881.911.952.072.292.723.54.274.895.35.275.936.617.849.6811.4813.114.214.1714.7114.413.1912.351218.2817.0816.316.0314.9713.1412.5112.0312.4413.2916.1317.9919.2822.7724.49
0.090.180.40.390.460.40.741.011.041.421.781.421.972.52.533.614.764.956.987.267.946.734.1111.2911.067.891.312.674.348.6111.3713.8513.0612.1312.896.231.891.370.972.451.5
00000000000000000000000000000000000000000
0000000000000000003.363.110.860.680.520.940.710.5347.7639.4634.329.0823.820.3922.617.3114.1811.4314.214.622.9320.2718.01
0000000000.156.657.216.836.746.788.297.587.374.134.131.091.091.091.431.451.4412.0412.3812.1612.1312.312.9917.7218.1618.2818.2519.4320.2421.2621.221.2
0.670.320.310.30.270.270.320.530.640.850.871.011.151.41.61.892.352.753.484.4855.893.692.487.736.234.55.134.855.427.525.26.045.145.317.555.289.6310.996.759.31
2.482.412.592.592.672.743.354.265.196.6914.1914.9315.2116.5717.5221.6224.3826.5631.0633.1829.0629.123.829.3433.3128.0883.8876.7271.9571.2869.9665.5671.9364.7663.1156.7656.9163.8275.4373.4474.51
4.214.594.95.115.686.136.768.039.511.0919.9321.8623.8324.2925.7431.8535.6340.1544.0247.5640.5942.5744.8544.5748.3547.2112.31105.78105.13106.13105.6598.17101.6895.3887.8782.6484.491.59105.69109.16106.68
                                                                                 
00000.150.150.150.170.190.24.584.674.744.970.030.030.030.030.030.030.030.030.030.030.030.031.781.791.791.791.791.791.791.791.791.791.791.791.791.791.79
0.150.150.150.1500000000005.225.615.926.276.916.946.966.876.97.178.018.3239.6840.740.6640.6540.5140.4240.2239.9439.938.8139.6639.5944.2444.3844.51
2.412.682.983.383.924.585.396.397.598.479.3910.9412.7414.8217.2920.1923.4527.3631.4935.4434.1436.6337.9839.139.1443.741.4137.5438.9939.9939.2646.0245.3544.1341.3542.5846.647.3653.761.0853.9
24.72626.3000000000009-21.38.130.810.6-9965.5-45.952.3-1,164.3-826.1-2,553.9-2,800-3,247-3,153-4,755-2,251-4,434-4,189-5,223-4,849-5,467-6,211-6,634-4,429-4,768-5,161
00000000000000000000000000333121735411141-3-61-78180000
2.592.863.163.534.074.735.556.557.778.6713.9715.6117.4819.7922.5525.8129.4133.6938.4442.3141.1943.4844.9645.1346.3649.4980.176.8178.3177.7479.3683.9183.2180.6378.1377.6381.8682.195.29102.4895.03
0.510.590.680.770.910.830.941.141.41.462.382.723.112.943.273.684.164.611.92.410.740.420.470.50.620.622.242.312.021.752.272.632.532.813.13.323.744.594.614.263.92
0000000000000000003.213.373.775.295.286.658.539.179.468.5110.179.749.3410.4411.1810.1710.2610.0712.4513.0513.8613.6115.19
0.120.10.20.270.450.620.640.91.081.331.782.591.221.291.41.761.742.032.372.933.363.854.524.291.282.232.362.422.062.541.732.632.913.662.193.512.423.252.994.425.21
0000000000000000000000000020700000000000000
0.370.410.330.370.850.460.330.790.340.831.740.150.420.610.90.622.863.324.073.671.72.182.971.291.822.31.382.41.994.324.522.72.580.573.065.313.616.432.411.951.37
11.11.21.422.211.911.912.832.813.625.95.454.754.835.576.078.769.9511.5412.389.5711.7413.2412.7212.2614.3215.6415.6416.2518.3517.8718.419.217.218.6122.2122.2227.3323.8724.2425.69
0.390.180.170.170.170.140.120.120.490.51.121.151.371.161.353.223.143.64.84.885.14.695.135.553.923.9416.115.4815.5316.2520.5418.723.8324.2721.3519.8122.7425.3630.6928.7533.68
0.370.480.570.57000001.341.742.913.694.035.066.067.036.756.797.186.436.446.096.3311.597.7719.0917.8516.4216.076.784.476.545.082.221.71.471.023.441.80.87
00001.191.221.211.241.270000000000000000000008.147.817.358.5111.1212.0411.9712.489.438.328.79
0.760.660.740.741.351.361.331.371.771.842.874.065.065.186.419.2810.1710.3511.5912.0611.5311.1311.2211.8815.511.7135.1933.3431.9432.3235.4530.9837.7137.8734.6933.5536.1838.8643.5738.8643.35
1.761.761.952.153.563.273.244.24.585.468.769.519.8110.0111.9815.3518.9320.323.1324.4321.122.8824.4624.627.7626.0350.8348.9848.1950.6753.3249.3856.9155.0753.355.7658.466.1867.4463.169.04
4.354.625.115.697.6388.7810.7512.3614.1322.7325.1227.2929.834.5341.1648.3453.9961.5766.7462.2966.3669.4269.7374.1275.52130.93125.79126.49128.41132.68133.29140.12135.7131.43133.39140.25148.29162.73165.58164.07
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Merck & Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Merck & Co's financial health and stability.

Assets

Merck & Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Merck & Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Merck & Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Merck & Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (B)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.680.911.211.51.782.121.983.14.424.85.546.468.138.626.827.287.156.835.834.634.433.47.9313.020.986.396.34.5211.934.463.942.426.199.784.5212.3614.530.38
0.190.210.20.220.250.250.30.390.680.670.730.841.021.141.271.131.231.311.451.712.271.991.632.587.387.436.986.996.696.385.444.644.523.653.493.213.913.87
0.04-0.07-0.14-0.07-0.130-0.020000000-0.090.460.390.130.050.01-0.53-1.780.531.82-1.09-1.540.67-0.33-2.6-0.76-1.52-2.62-0.51-0.56-0.570.19-1.57-1.9
0.140.120.22-0.270.230.06-0.17-1.15-0.95-2.5-1.02-1.3-2.87-3.14-0.40.050.410.491.51.18-0.141.36-3.98-2.710.93-0.77-4.14-0.791.82-0.27-2.6-5.02-1.55-2.07-4.6-3.84-2.78-2.21
-0.03-0.02-0.10-0.08-00.410.71-0-0.020.180.32-0.95-0.50.09-0.260.11.13-0.040.080.732.040.81-10.913.131.240.551.55-9.712.925.427.352.623.027.852.675.5513.51
00.050.080.060.060.070.060.090.140.090.120.130.190.280.450.470.40.360.280.350.390.410.250.350.760.60.90.920.850.650.690.720.780.840.820.780.941.1
0.270.430.620.830.830.880.930.860.8621.11.32.12.482.172.11.821.91.72.43.51.80.961.62.72.52.37.91.81.84.91.54.52.72.43.24.34
1.021.151.391.382.062.432.53.054.142.945.436.325.336.137.698.669.299.898.87.616.7776.573.3910.8212.3810.0211.657.8612.4210.386.4510.9213.4410.2514.1119.113.01
-210-253-372-433-670-1,041-1,066-1,012-1,009-1,005-1,196-1,448-1,973-2,560-2,727-2,401-2,128-1,915-1,726-1,402-980-1,011-1,298-1,460-1,678-1,723-1,954-1,548-1,317-1,283-1,614-1,888-2,615-3,473-4,429-4,448-4,388-3,863
-0.3-0.33-0.11-0.56-1-1.3-1.35-2.59-0.03-1.32-1.98-1.6-0.01-2.82-3.64-3.9-3.77-4.26-1.642.27-4.88-2.81-1.833.16-3.5-2.89-6.81-3.15-0.37-4.76-3.212.684.31-2.63-9.44-16.56-4.96-14.08
-0.09-0.080.27-0.13-0.33-0.26-0.29-1.580.98-0.32-0.78-0.151.96-0.26-0.91-1.49-1.64-2.350.093.67-3.9-1.8-0.544.62-1.82-1.17-4.85-1.60.94-3.48-1.64.576.930.84-5.01-12.11-0.57-10.22
00000000000000000000000000000000000000
0.030.46-0.39-0.150.48-0.120.51.23-1.40.48-0.020.491.582.130.91.94-0.39-1.780.121.28-1.27-1.180.471.780.75-0.473.164.53-3.933.49-1.31-1.130.841.255.011.63-2.254.18
-474-97929-172-707-135-810-287-565-287-2,051-3,159-3,135-3,259-1,404-3,590-1,773-1,645-2,234-878-632-531-2,622186-1,230-1,600-1,281-5,306-6,143-3,701-2,495-3,515-8,500-4,419-1,192-638384-1,221
-0.71-0.84-0.83-0.96-0.95-1.14-1.36-0.21-3.4-1.4-3.84-4.86-3.92-3.87-3.45-5.07-5.53-6.83-5.59-3.04-5.6-4.87-5.52-1.64-5.44-6.9-3.27-5.99-15.11-5.27-9.04-10.01-13.16-8.86-2.832.59-9.12-4.81
00.010.030.020.030.020.020.02-0.01-0.06-0.04-0.15-0.11-0.15-0.15-0.28-0.17-0.15-0.16-0.09-0.380.16-0.09-0.39-0.23-0.14-0.03-0.060.130.06-0.12-0.2-0.330.01-0.448.21-0.24-0.33
-266-334-504-650-749-893-1,064-1,174-1,434-1,539-1,728-2,039-2,253-2,589-2,798-3,145-3,191-3,250-3,310-3,349-3,322-3,307-3,278-3,215-4,734-4,691-5,116-5,157-5,170-5,117-5,124-5,167-5,172-5,695-6,215-6,610-7,012-7,445
0.040.030.45-0.170.12-0.01-0.220.250.770.24-0.5-0.231.48-0.580.51-0.390.1-1.041.686.71-3.67-0.58-0.974.941.592.63-0.082.17-8.181.08-2.01-0.421.871.97-1.770.014.61-5.86
811.68941,014.1947.71,384.81,392.51,437.82,035.83,130.61,938.74,2314,867.83,354.93,570.24,959.56,262.17,157.67,977.77,0736,205.85,7855,988.25,273.41,931.49,14410,6608,06810,1066,54311,1388,7624,5598,3079,9675,8249,66114,7079,143
00000000000000000000000000000000000000

Merck & Co stock margins

The Merck & Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merck & Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merck & Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Merck & Co's sales revenue. A higher gross margin percentage indicates that the Merck & Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Merck & Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Merck & Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Merck & Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Merck & Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Merck & Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Merck & Co Margin History

Merck & Co Gross marginMerck & Co Profit marginMerck & Co EBIT marginMerck & Co Profit margin
2029e73.53 %39.62 %35.92 %
2028e73.53 %41.62 %37.64 %
2027e73.53 %43.94 %38.18 %
2026e73.53 %43.61 %37.46 %
2025e73.53 %42 %35.67 %
2024e73.53 %37.26 %30.66 %
202373.53 %6.76 %0.61 %
202270.98 %34.26 %24.49 %
202172.81 %31.96 %26.79 %
202072.1 %26.31 %17.02 %
201971.73 %25.78 %25.16 %
201869.11 %26.74 %14.71 %
201768.5 %24.82 %5.97 %
201666.08 %24.98 %9.85 %
201563.22 %21.79 %11.25 %
201464.05 %22.13 %28.22 %
201363.61 %20.93 %10 %
201265.21 %22.21 %13.04 %
201164.89 %21.02 %13.02 %
201060 %14.67 %1.87 %
200967.12 %17.13 %46.86 %
200876.59 %26.05 %32.65 %
200774.62 %24.56 %13.5 %
200673.49 %16.54 %19.59 %
200576.61 %26.7 %21.04 %
200478.38 %29.42 %25.38 %

Merck & Co Stock Sales Revenue, EBIT, Earnings per Share

The Merck & Co earnings per share therefore indicates how much revenue Merck & Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Merck & Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Merck & Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Merck & Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Merck & Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Merck & Co Revenue, EBIT and net profit per share

DateMerck & Co Sales per ShareMerck & Co EBIT per shareMerck & Co Earnings per Share
2029e29.64 undefined0 undefined10.65 undefined
2028e30.77 undefined0 undefined11.58 undefined
2027e30.05 undefined0 undefined11.47 undefined
2026e28.5 undefined0 undefined10.68 undefined
2025e26.86 undefined0 undefined9.58 undefined
2024e25.55 undefined0 undefined7.83 undefined
202323.6 undefined1.6 undefined0.14 undefined
202223.32 undefined7.99 undefined5.71 undefined
202119.19 undefined6.13 undefined5.14 undefined
202016.34 undefined4.3 undefined2.78 undefined
201915.16 undefined3.91 undefined3.82 undefined
201815.79 undefined4.22 undefined2.32 undefined
201714.6 undefined3.62 undefined0.87 undefined
201614.28 undefined3.57 undefined1.41 undefined
201513.9 undefined3.03 undefined1.56 undefined
201414.43 undefined3.19 undefined4.07 undefined
201314.7 undefined3.08 undefined1.47 undefined
201215.37 undefined3.41 undefined2 undefined
201115.53 undefined3.26 undefined2.02 undefined
201014.74 undefined2.16 undefined0.28 undefined
200912.07 undefined2.07 undefined5.65 undefined
200811.13 undefined2.9 undefined3.63 undefined
200711.05 undefined2.71 undefined1.49 undefined
200610.35 undefined1.71 undefined2.03 undefined
200510 undefined2.67 undefined2.1 undefined
200410.32 undefined3.04 undefined2.62 undefined

Merck & Co business model

The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards. Merck & Co is one of the most popular companies on Eulerpool.com.

Merck & Co SWOT Analysis

Strengths

Merck & Co Inc, a leading pharmaceutical company, possesses the following strengths:

  • Strong brand reputation and recognition worldwide
  • Extensive experience and expertise in drug development and research
  • Robust portfolio of patented drugs and intellectual property
  • Broad geographical presence, with operations in numerous countries
  • Diverse product offerings across multiple therapeutic areas

Merck & Co Inc faces the following weaknesses:

  • Dependency on a limited number of flagship drugs for significant revenue
  • Relatively high research and development costs
  • Vulnerability to generic competition as patents expire
  • Regulatory challenges and delays in drug approvals
  • Potential exposure to litigation related to product safety and side effects

Merck & Co Inc can explore the following opportunities:

  • Expansion into emerging markets with growing healthcare needs
  • Investment in research and development of innovative drugs and therapies
  • Strategic collaborations and partnerships for joint ventures and licensing
  • Advancements in technology for drug delivery and precision medicine
  • Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Weaknesses

Merck & Co Inc faces the following weaknesses:

  • Dependency on a limited number of flagship drugs for significant revenue
  • Relatively high research and development costs
  • Vulnerability to generic competition as patents expire
  • Regulatory challenges and delays in drug approvals
  • Potential exposure to litigation related to product safety and side effects

Merck & Co Inc can explore the following opportunities:

  • Expansion into emerging markets with growing healthcare needs
  • Investment in research and development of innovative drugs and therapies
  • Strategic collaborations and partnerships for joint ventures and licensing
  • Advancements in technology for drug delivery and precision medicine
  • Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Opportunities

Merck & Co Inc can explore the following opportunities:

  • Expansion into emerging markets with growing healthcare needs
  • Investment in research and development of innovative drugs and therapies
  • Strategic collaborations and partnerships for joint ventures and licensing
  • Advancements in technology for drug delivery and precision medicine
  • Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Threats

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Merck & Co Revenue by Segment

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Merck & Co Revenue by Segment

Segmente20172016201520142012
Januvia2.15 B USD3.91 B USD3.86 B USD3.93 B USD4.09 B USD
Zetia352 M USD2.56 B USD2.53 B USD2.65 B USD2.57 B USD
Other pharmaceutical1.25 B USD4.7 B USD4.55 B USD--
Janumet2.16 B USD2.2 B USD2.15 B USD2.07 B USD1.66 B USD
Remicade837 M USD1.27 B USD1.79 B USD2.37 B USD2.08 B USD
ProQuad/M-M-R II/Varivax1.68 B USD1.64 B USD1.51 B USD1.39 B USD1.27 B USD
Singulair40 M USD915 M USD931 M USD1.09 B USD3.85 B USD
Vytorin751 M USD1.14 B USD1.25 B USD1.52 B USD1.75 B USD
Gardasil/Gardasil 92.31 B USD2.17 B USD1.91 B USD--
Isentress-1.39 B USD1.51 B USD1.67 B USD1.52 B USD
Keytruda2.31 B USD1.4 B USD566 M USD55 M USD-
Nasonex387 M USD537 M USD858 M USD1.1 B USD1.27 B USD
Gardasil---1.74 B USD1.63 B USD
Cozaar/Hyzaar18 M USD511 M USD667 M USD806 M USD1.28 B USD
Zostavax246 M USD685 M USD749 M USD765 M USD651 M USD
NuvaRing197 M USD777 M USD732 M USD723 M USD623 M USD
Cancidas422 M USD558 M USD573 M USD681 M USD619 M USD
Pneumovax 23821 M USD641 M USD542 M USD746 M USD-
RotaTeq204 M USD652 M USD610 M USD659 M USD601 M USD
Cubicin382 M USD1.09 B USD1.13 B USD--
Simponi-766 M USD690 M USD689 M USD331 M USD
Emend342 M USD549 M USD535 M USD553 M USD489 M USD
Invanz241 M USD561 M USD569 M USD529 M USD445 M USD
Zepatier1.66 B USD555 M USD---
Implanon/Nexplanon496 M USD606 M USD588 M USD502 M USD-
Temodar271 M USD283 M USD312 M USD350 M USD917 M USD
Noxafil309 M USD595 M USD487 M USD402 M USD258 M USD
Fosamax241 M USD284 M USD359 M USD470 M USD676 M USD
Dulera287 M USD436 M USD536 M USD460 M USD207 M USD
Arcoxia-450 M USD471 M USD519 M USD453 M USD
Follistim AQ174 M USD355 M USD383 M USD412 M USD468 M USD
Bridion239 M USD482 M USD353 M USD340 M USD261 M USD
Primaxin280 M USD297 M USD313 M USD329 M USD384 M USD
PegIntron--182 M USD381 M USD653 M USD
Zocor-186 M USD217 M USD258 M USD383 M USD
Propecia--183 M USD264 M USD424 M USD
Clarinex--187 M USD232 M USD393 M USD
Cosopt/Trusopt---257 M USD444 M USD
Victrelis---153 M USD502 M USD
Maxalt----638 M USD
Pneumovax----580 M USD
Isentress/Isentress HD565 M USD----
Adempas500 M USD----
Remeron---193 M USD232 M USD
Implanon----348 M USD
Cerazette----271 M USD
Claritin Rx----244 M USD
Atozet225 M USD----
Proscar----217 M USD
Integrilin----211 M USD
Avelox----201 M USD
Vasotec/Vaseretic----192 M USD
Asmanex----185 M USD

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Merck & Co Revenue by Segment

Segmente20172016201520142012
Remicade and Simponi-----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Merck & Co Revenue by Segment

Segmente20172016201520142012
Pharmaceutical segment35.39 B USD35.15 B USD313 M USD--
Segment----47.01 B USD
Operating segments---41.63 B USD-
Segment One----40.6 B USD
Pharmaceutical---36.04 B USD-
Other segments4.27 B USD3.86 B USD3.66 B USD--
Other pharmaceutical---4.78 B USD4.14 B USD
All Other Segments----6.41 B USD
All Other---5.59 B USD-
Primary Care and Women's Health---3.93 B USD-
Vaccines---746 M USD580 M USD
Diversified Brands---1.09 B USD-
Primary care and women's health----638 M USD
Other---610 M USD-
Oncology---553 M USD-
Hospital and Specialty---329 M USD-
Other Miscellaneous----254 M USD
Hospital and specialty----211 M USD
Diversified brands----192 M USD

Merck & Co Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Merck & Co Revenue by Segment

DateAsia PacificAsia Pacific (other than China and Japan)Asia Pacific (other than Japan and China)ChinaEurope, Middle East and AfricaEurope, Middle East, and AfricaInt’lIntu2019lJapanLatin AmericaOther CountriesUnited States
2023-3.23 B USD-6.8 B USD13.25 B USD-31.64 B USD-3.16 B USD3.09 B USD2.1 B USD28.48 B USD
2022-3.61 B USD-5.19 B USD14.49 B USD-32.08 B USD-3.63 B USD2.58 B USD2.57 B USD27.21 B USD
2021-2.41 B USD-4.38 B USD13.34 B USD-26.28 B USD-2.73 B USD2.21 B USD1.22 B USD22.43 B USD
2020-2.86 B USD-3.62 B USD13.6 B USD-26.97 B USD-3.38 B USD2.27 B USD1.23 B USD21.03 B USD
2019--2.94 B USD3.21 B USD12.71 B USD-26.52 B USD-3.58 B USD2.47 B USD1.61 B USD20.33 B USD
2018--2.91 B USD2.18 B USD12.21 B USD-24.08 B USD-3.21 B USD2.42 B USD1.15 B USD18.21 B USD
20174.34 B USD---11.48 B USD--225 M USD3.12 B USD2.34 B USD1.42 B USD239 M USD
20163.92 B USD---10.95 B USD---2.85 B USD2.16 B USD1.46 B USD18.48 B USD
20153.82 B USD----10.68 B USD--2.67 B USD2.82 B USD1.99 B USD17.52 B USD
20143.95 B USD----13.17 B USD--3.47 B USD3.15 B USD1.42 B USD17.07 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Merck & Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Merck & Co historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Merck & Co shares outstanding

The number of shares was Merck & Co in 2024 — This indicates how many shares 2.547 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Merck & Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Merck & Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Merck & Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Merck & Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Merck & Co stock splits

In Merck & Co's history, there have been no stock splits.

Merck & Co dividend history and estimates

In 2024, Merck & Co paid a dividend amounting to 3.12 USD. Dividend means that Merck & Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Merck & Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Merck & Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Merck & Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Merck & Co Dividend History

DateMerck & Co Dividend
2029e3.36 undefined
2028e3.37 undefined
2027e3.37 undefined
2026e3.35 undefined
2025e3.37 undefined
2024e3.38 undefined
20232.96 undefined
20222.8 undefined
20212.64 undefined
20202.48 undefined
20192.26 undefined
20181.99 undefined
20171.89 undefined
20161.85 undefined
20151.81 undefined
20141.77 undefined
20131.73 undefined
20121.69 undefined
20111.56 undefined
20101.52 undefined
20091.52 undefined
20081.52 undefined
20071.52 undefined
20061.52 undefined
20051.52 undefined
20041.5 undefined

Merck & Co dividend payout ratio

In 2024, Merck & Co had a payout ratio of 54.53%. The payout ratio indicates the percentage of the company's profits that Merck & Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Merck & Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Merck & Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Merck & Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Merck & Co Payout Ratio History

DateMerck & Co Payout ratio
2029e56.73 %
2028e56.44 %
2027e55.97 %
2026e57.78 %
2025e55.59 %
2024e54.53 %
202363.2 %
202249.04 %
202151.36 %
202089.21 %
201959.32 %
201885.78 %
2017217.24 %
2016131.21 %
2015116.03 %
201443.49 %
2013117.69 %
201284.5 %
201177.23 %
2010542.86 %
200926.9 %
200841.87 %
2007102.01 %
200674.88 %
200572.38 %
200457.25 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Merck & Co.

Merck & Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20241.52 1.57  (3.36 %)2024 Q3
6/30/20242.18 2.28  (4.78 %)2024 Q2
3/31/20241.89 2.07  (9.3 %)2024 Q1
12/31/2023-0.11 0.03  (127.2 %)2023 Q4
9/30/20231.97 2.13  (8.09 %)2023 Q3
6/30/2023-2.2 -2.06  (6.33 %)2023 Q2
3/31/20231.33 1.4  (4.89 %)2023 Q1
12/31/20221.55 1.62  (4.29 %)2022 Q4
9/30/20221.72 1.85  (7.36 %)2022 Q3
6/30/20221.72 1.87  (8.68 %)2022 Q2
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Merck & Co stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

80

👫 Social

93

🏛️ Governance

44

Environment

Scope 1 - Direct Emissions
712,400
Scope 2 - Indirect emissions from purchased energy
352,000
Scope 3 - Indirect emissions within the value chain
6,787,100
Total CO₂ emissions
1,064,400
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees50
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Merck & Co shareholders

%
Name
Stocks
Change
Date
9.62928 % The Vanguard Group, Inc.243,586,2151,396,1446/30/2024
5.03423 % BlackRock Institutional Trust Company, N.A.127,347,997-839,7526/30/2024
4.64453 % State Street Global Advisors (US)117,489,93864,4086/30/2024
2.86531 % Wellington Management Company, LLP72,481,979-13,866,2806/30/2024
2.25410 % Geode Capital Management, L.L.C.57,020,708609,4796/30/2024
1.87413 % Fidelity Management & Research Company LLC47,408,863-1,269,8336/30/2024
1.33643 % Norges Bank Investment Management (NBIM)33,806,9765,295,0886/30/2024
0.96956 % BofA Global Research (US)24,526,4973,263,7096/30/2024
0.92607 % Legal & General Investment Management Ltd.23,426,16750,0356/30/2024
0.83577 % T. Rowe Price Associates, Inc.21,141,859-5,011,5196/30/2024
1
2
3
4
5
...
10

Merck & Co Executives and Management Board

Mr. Robert Davis

(56)
Merck & Co Chairman of the Board, President, Chief Executive Officer (since 2014)
Compensation 18.65 M

Mr. Chirfi Guindo

(57)
Merck & Co Senior Vice President, Chief Marketing Officer - Human Health
Compensation 13.94 M

Dr. Dean Li

(61)
Merck & Co Executive Vice President, President - Merck Research Laboratories (since 2021)
Compensation 7.77 M

Mr. Richard Deluca

(60)
Merck & Co Executive Vice President, President - Merck Animal Health
Compensation 6.84 M

Ms. Jennifer Zachary

(45)
Merck & Co Executive Vice President, General Counsel, Corporate Secretary
Compensation 5.9 M
1
2
3
4
5
...
6

Merck & Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
PDS Biotechnology Stock
PDS Biotechnology
SupplierCustomer0,790,63-0,33-0,35-0,370,08
SUSE Stock
SUSE
SupplierCustomer0,760,600,83-0,130,04
Progress Software Stock
Progress Software
SupplierCustomer0,690,240,770,210,380,26
KYORIN Stock
KYORIN
SupplierCustomer0,690,56-0,420,220,11-0,30
DKSH Holding AG Stock
DKSH Holding AG
SupplierCustomer0,67
Yumanity Therapeutics Stock
Yumanity Therapeutics
SupplierCustomer0,660,27 -0,28-0,42-0,37
Vaccinex Stock
Vaccinex
SupplierCustomer0,660,60-0,29-0,06-0,37-0,20
Laboratorios Farmaceutico Stock
Laboratorios Farmaceutico
SupplierCustomer0,660,22-0,52-0,330,160,27
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,660,240,940,780,770,73
Zymeworks Stock
Zymeworks
SupplierCustomer0,650,61-0,55-0,39-0,46-0,39
1
2
3
4
5
...
10

Most common questions regarding Merck & Co

What values and corporate philosophy does Merck & Co represent?

Merck & Co Inc represents a strong commitment to scientific innovation, integrity, and improving global health. As a leading pharmaceutical company, Merck aims to discover, develop, and provide high-quality healthcare solutions. The company's corporate philosophy revolves around putting patients first, valuing diversity and inclusion, and taking responsibility for environmental sustainability. Merck is dedicated to delivering innovative medicines and vaccines, ensuring affordability and access for patients worldwide. With a focus on research, collaboration, and ethical business practices, Merck strives to make a positive impact on society and enhance the well-being of individuals around the globe.

In which countries and regions is Merck & Co primarily present?

Merck & Co Inc is primarily present in several countries and regions across the world. The company has a strong global presence, with operations in the United States, Europe, Asia-Pacific, Latin America, and Africa. Merck & Co Inc has established a significant presence in key markets such as the United States, Germany, Japan, China, and Brazil. With its wide international footprint, Merck & Co Inc is committed to delivering its innovative healthcare solutions to patients and healthcare professionals worldwide.

What significant milestones has the company Merck & Co achieved?

Merck & Co Inc, a leading pharmaceutical company, has achieved significant milestones throughout its history. The company's notable achievements include the development and launch of groundbreaking drugs like Gardasil, a vaccine for preventing cervical cancer, and Keytruda, an innovative immunotherapy for treating various types of cancer. Merck & Co Inc has also contributed to medical advancements with its research and development efforts, resulting in breakthroughs in areas such as HIV/AIDS treatment and vaccines. The company's commitment to improving global health has resulted in partnerships and initiatives aimed at tackling diseases like malaria and Ebola. Merck & Co Inc continues to make strides in the pharmaceutical industry, focusing on innovative solutions for unmet medical needs.

What is the history and background of the company Merck & Co?

Merck & Co Inc is a renowned pharmaceutical company with a rich history and notable background. Established in 1891, Merck & Co Inc has been dedicated to enhancing global health and improving people's lives. The company has evolved into one of the leading players in the pharmaceutical industry, specializing in research, development, and manufacturing of innovative medications and vaccines. Merck & Co Inc has proactively contributed to medical advancements, from pioneering treatments for diseases like HIV/AIDS to addressing various health challenges. With a commitment to scientific excellence and patient well-being, Merck & Co Inc continues to shape the future of healthcare worldwide.

Who are the main competitors of Merck & Co in the market?

The main competitors of Merck & Co Inc in the market are Johnson & Johnson, Pfizer Inc, Novartis AG, and Bristol-Myers Squibb Company.

In which industries is Merck & Co primarily active?

Merck & Co Inc is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Merck & Co?

The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.

What is the P/E ratio of Merck & Co 2025?

The Merck & Co P/E ratio is 11.21.

What is the P/S ratio of Merck & Co 2025?

The Merck & Co P/S ratio is 4.

What is the Quality Investing of Merck & Co?

The Quality Investing for Merck & Co is 3/10.

What is the revenue of Merck & Co 2025?

The expected Merck & Co revenue is 67.94 B USD.

How high is the profit of Merck & Co 2025?

The expected Merck & Co profit is 24.23 B USD.

What is the business model of Merck & Co

Merck & Co Inc is one of the leading global pharmaceutical companies focused on the discovery, development, and marketing of drugs, vaccines, and biologics for a variety of diseases and disorders. The company is headquartered in Kenilworth, New Jersey and operates worldwide in over 140 countries.

What is the Merck & Co dividend?

Merck & Co pays a dividend of 2.8 USD distributed over 4 payouts per year.

How often does Merck & Co pay dividends?

Merck & Co pays out a dividend 4 times a year.

What is the Merck & Co ISIN?

The ISIN of Merck & Co is US58933Y1055.

What is the Merck & Co WKN?

The WKN of Merck & Co is A0YD8Q.

What is the Merck & Co ticker?

The ticker of Merck & Co is MRK.

How much dividend does Merck & Co pay?

Over the past 12 months, Merck & Co paid a dividend of 2.96 USD . This corresponds to a dividend yield of about 2.77 %. For the coming 12 months, Merck & Co is expected to pay a dividend of 3.35 USD.

What is the dividend yield of Merck & Co?

The current dividend yield of Merck & Co is 2.77 %.

When does Merck & Co pay dividends?

Merck & Co pays a quarterly dividend. This is distributed in the months of April, July, October, January.

How secure is the dividend of Merck & Co?

Merck & Co paid dividends every year for the past 26 years.

What is the dividend of Merck & Co?

For the upcoming 12 months, dividends amounting to 3.35 USD are expected. This corresponds to a dividend yield of 3.32 %.

In which sector is Merck & Co located?

Merck & Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Merck & Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Merck & Co from 1/8/2025 amounting to 0.81 USD, you needed to have the stock in your portfolio before the ex-date on 12/16/2024.

When did Merck & Co pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of Merck & Co in the year 2024?

In the year 2024, Merck & Co distributed 2.96 USD as dividends.

In which currency does Merck & Co pay out the dividend?

The dividends of Merck & Co are distributed in USD.

All fundamentals about Merck & Co

Our stock analysis for Merck & Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck & Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.